Why Dementia Costs More Than Cancer and Heart Disease Combined

Dementia is now the single most expensive disease in America, costing more than both cardiovascular disease and cancer combined. That gap is widening, and the numbers make clear why.

The scale is enormous. CDC data from May 2026 projects cardiovascular disease costs at roughly $2 trillion. The American Heart Association expects heart disease costs to roughly triple to $1.8 trillion by 2050. To put that in perspective: U.S. healthcare spending hit $5.3 trillion in 2024. So just cardiovascular care alone would eat up more than one-third of today's entire national healthcare bill. Yet dementia already costs more — because it strips away independence and keeps people dependent on care for years, not months.

The Heavy Load of Chronic Disease

Chronic diseases — conditions that develop slowly and persist over years — are the dominant cost driver in American healthcare. The CDC's 2026 fact sheet is clear: chronic conditions cause most illness, disability, and death in the country and eat up the majority of healthcare dollars. Heart disease and stroke killed more than 850,000 Americans in 2024 alone. Globally, cardiovascular disease claimed about 19 million lives in 2021, nearly double the 10 million deaths from cancer that year, according to WHO data from September 2025.

The direct cost of treating heart disease is steep. Between 2021 and 2022, the CDC documented that cardiovascular care and medications cost more than $168 billion. For patients with heart failure specifically, out-of-pocket costs — the money families pay directly — average $4,423 annually, per a November 2024 study. For a family already managing a chronic illness, that's real money draining from household finances.

Cancer carries a global economic toll. The WHO estimated that at roughly $1.16 trillion in 2010, with U.S.-only costs around $70 billion annually. Older research from 2020 put annual U.S. costs at $193 billion for heart disease, $176 billion for diabetes, and $159 billion for dementia. Those numbers are now several years old, and the dementia figure has moved significantly higher.

Why Dementia's Cost Structure Is Fundamentally Different

Here's where dementia breaks the pattern. Unlike heart disease or cancer — which often involve acute crisis, expensive surgery or chemotherapy, then ongoing medical management — dementia is almost entirely about custodial care. Think of it this way: a heart attack patient may spend weeks in intensive care and months in recovery, but most survivors eventually return to independence. A dementia patient moves gradually into total dependence and stays there for years. That means skilled nursing homes, memory care facilities, and family caregiving — paid and unpaid — that stretches across a decade or more.

The result is costs that compound over years rather than months. Research reported by MarketWatch on June 26, 2026 noted that the steepest quality-of-life declines — losses in memory, thinking ability, and independence — are precisely the conditions that maximize caregiving hours and caregiver exhaustion.

The global cost of chronic disease is projected at $47 trillion, according to research published in January 2024. Dementia, an aging population, and the fact that fewer working-age adults will be available to care for more seniors are the underlying forces driving that figure. In the United States, the retirement wave of baby boomers is pushing dementia prevalence upward faster than any drug currently in development is likely to push it downward.

What This Means for People Who Are Saving and Investing

The broader context matters here. The $1.8 trillion cardiovascular projection by 2050 and the ~$2 trillion CDC figure represent what public and private insurers will have to pay for heart disease. Dementia costs sit above that. This arithmetic has real consequences for people making financial decisions.

If you're buying long-term care insurance, insurers are pricing those products based on dementia risk. If you're contributing to a pension fund, that fund is modeling how long people will live — and therefore how much it needs to pay out. If you're investing in healthcare real estate, you need to think about whether there will be enough memory care facilities to meet demand. The underlying numbers are the same for all of them.

Recent drug approvals suggest that new dementia treatments may slow the disease in some patients. Whether these interventions bend the overall cost curve, or simply delay the inevitable, we don't yet know. The $47 trillion global estimate was not built on the assumption that medicine solves the problem. It was built on the assumption that medicine does not, and that the aging of the world's population proceeds as currently projected. That is the baseline we should expect until evidence says otherwise.

Taken together, the numbers describe a structural financial pressure that will fall on households, insurance companies, governments, and financial markets at the same time — and for which no quick fix exists.